Correlation of Corneal Sensitivity With Vision-Related Quality of Life, Ocular Surface Symptoms, and Clinical Severity in Parkinson's Disease.
Correlation of Corneal Sensitivity With Vision-Related Quality of Life, Ocular Surface Symptoms, and Clinical Severity in Parkinson's Disease.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Mexico City, MX · Author affiliation
Department of Anterior Segment. Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City, Mexico.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
PurposeTo investigate the relationship between corneal sensitivity (CS), vision-related quality of life, ocular surface symptoms, and clinical severity in patients with Parkinson's disease (PwP).MethodsProspective observational cohort study. CS was measured using a noncontact esthesiometer. Vision-related quality of life and ocular surface symptoms were assessed with the NEI VFQ-25 and OSDI questionnaires. Parkinson's disease severity was graded with the Hoehn and Yahr (HY) scale. Associations were analyzed using Pearson correlation and ANOVA.ResultsA total of 356 eyes from 178 PwP were included. Mean age was 62.77 ± 11.34 years, and 51.4% were male. Mean CS was 6.47 ± 2.24 mBar, NEI VFQ-25 score was 67.11 ± 9.35, and OSDI score was 25.17 ± 18.19. CS was significantly associated with the NEI VFQ-25 composite score (r = 0.449, P <0.001) but not with the OSDI score (r = 0.122, P = 0.141). NEI VFQ-25 and OSDI scores showed moderate correlation (r = 0.477, P <0.001). CS also correlated with general vision, near vision, distance vision, mental health, and peripheral vision subscales (P <0.05). CS varied across HY stages (P <0.001), with stages 3 to 4 demonstrating significantly reduced sensitivity compared with stages 1 to 2 (all P <0.001).ConclusionsCS correlates with vision-related quality of life but not directly with ocular surface symptoms in PwP. Its progressive reduction with advancing HY stages suggests potential as a surrogate marker of disease severity. CS measurements may complement quality-of-life assessments and aid in the early detection of ocular surface compromise in this population.